Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
8.74
+0.49 (5.94%)
At close: Jun 26, 2026, 4:00 PM EDT
8.60
-0.14 (-1.60%)
After-hours: Jun 26, 2026, 7:42 PM EDT
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
| Name | Position |
|---|---|
| Dr. Ian Hodgson B.Sc., Ph.D. | Chief Operating Officer |
| Dr. Yuval Cohen Ph.D. | CEO & Director |
| Mr. G. Scott Goeken J.D., M.S. | General Counsel & Corporate Secretary |
| Mr. Nishant C. Saxena | Chief Business Officer |
| Mr. Sean F. Moran CPA, M.B.A. | Chief Financial Officer |
| Ms. Christina Bertsch M.A. | Vice President of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-06-17 | S-8 | crbp-20260617.htm |
| 2026-05-29 | S-8 | crbp-20260529.htm |
| 2026-05-26 | 8-K | crbp-20260526.htm |
| 2026-05-21 | 8-K | crbp-20260519.htm |
| 2026-05-14 | 8-K | crbp-20260513.htm |
| 2026-05-12 | 8-K | crbp-20260512.htm |
| 2026-05-12 | 10-Q | crbp-20260331.htm |
| 2026-04-16 | DEFA14A | crbp_defa14a_2026_04_16.htm |
| 2026-04-16 | 8-K | crbp-20260415.htm |
| 2026-04-14 | 8-K | crbp-20260414.htm |